Sensus Healthcare Inc Stock Price, News & Analysis

Sensus Healthcare (NASDAQ: SRTS), a medical device company focused on non-invasive treatments for skin conditions, has scheduled its Q2 2025 earnings release for August 7, 2025. The company will host a conference call at 4:30 PM Eastern time to discuss financial results and provide a business update.

Participants can pre-register for the call using a dedicated link to receive a unique dial-in number. Alternative dial-in options include 844-481-2811 (U.S./Canada) and 412-317-0676 (International). A webcast will be available live and archived in the Investor Relations section of the company's website. A telephone replay will be accessible until September 7th using replay code 8187211.

Sensus Healthcare (NASDAQ: SRTS) has achieved Medical Device Single Audit Program (MDSAP) certification for its complete portfolio of superficial radiation therapy (SRT) systems, including the SRT-100®, SRT-100+™, and SRT-100 Vision™.

The MDSAP certification streamlines regulatory compliance by allowing a single audit to satisfy requirements across multiple jurisdictions including the FDA, Health Canada, Brazil's ANVISA, Japan's PMDA, and Australia's TGA. This certification is expected to accelerate the company's international expansion by simplifying regulatory processes and reducing approval timelines in key global markets.

Upon receiving FDA clearance, Sensus Healthcare's TransDermal Infusion (TDI) product is also anticipated to receive MDSAP certification, further enhancing its international commercial potential.

Sensus Healthcare (NASDAQ:SRTS) has announced a strategic partnership with Radiology Oncology Systems (ROS) as its primary U.S. distribution partner for superficial radiotherapy (SRT) systems. ROS will sell Sensus's SRT-100™ and SRT-100 Vision™ systems to hospital-based radiation oncology departments and freestanding oncology centers nationwide.

The partnership leverages ROS's 30-year experience and presence across all 50 states to accelerate adoption of Sensus's non-invasive radiotherapy technologies. Initial orders are expected by Q4 2025, with potential expansion to international markets. This collaboration represents Sensus's strategic move to expand beyond dermatology into hospital and multidisciplinary oncology environments.

Sensus Healthcare (NASDAQ: SRTS) reported Q1 2025 financial results with revenues of $8.3 million, down from $10.7 million in Q1 2024. The company shipped 21 SRT systems during the quarter, including 15 to a large customer. Despite posting a net loss of $2.6 million ($0.16 per share), management remains optimistic, forecasting profitability for the next three quarters and full year. The company reported a 65% increase in treatment volume from FDA-based systems over the previous quarter. Key investments were made in sales, marketing, and R&D, including product development and lobbying efforts. Cash position stood at $19.1 million as of March 31, 2025. Management expects FDA revenue to contribute significantly in H2 2025 and aims to sign 3-5 additional multisite FDA customers this year.

Sensus Healthcare (NASDAQ: SRTS) is promoting Skin Cancer Awareness Month in May 2025 through educational initiatives and highlighting its non-invasive skin cancer treatment technologies. The company's flagship products, IG-SRT and SRT-100 Vision, provide non-invasive treatment options for non-melanoma skin cancers, delivering precise radiation therapy while preserving healthy tissue. Sensus offers its technologies through the Fair Deal Agreement, a shared-revenue program launched a year ago that requires no upfront capital from dermatology practices. The company is conducting awareness campaigns through newsletters, social media, and healthcare professional collaborations, while also providing educational resources about skin cancer prevention, including tips on sun protection, regular screenings, and avoiding UV exposure.

Sensus Healthcare (Nasdaq: SRTS), a medical device company focused on non-invasive and minimally-invasive treatments for skin conditions, has announced its participation in the 37th Annual ROTH Conference. The event is scheduled for March 17-18 in Dana Point, California.

The company, which specializes in treatments for both oncological and non-oncological skin conditions, will be conducting one-on-one meetings with registered investors during the conference. Interested registered attendees can schedule meetings with Sensus Healthcare management through their ROTH representative or by contacting Tirth Patel at Alliance Advisors.

Sensus Healthcare (NASDAQ: SRTS) announces its participation in the 2025 American Academy of Dermatology Annual Meeting, showcasing its commercial and pre-commercial products at Booth #2451. The company will present its full line of Superficial Radiotherapy (SRT) systems, including the SRT-100®, SRT-100+, and SRT-100 Vision™.

The exhibition will feature 'The A.I. Experience,' highlighting new innovations including a prototype handheld ultrasound device for skin lesion identification and the TransDermal Infusion (TDI) product with Sentinel™ IT Solutions. The TDI system, pending regulatory approval, will enable platelet-rich plasma application for hair restoration and has shown potential applications for hyperhidrosis treatment.

The event will take place March 7-11, 2025, at the Orange County Convention Center in Orlando, Florida, featuring over 350 exhibitors and expecting nearly 20,000 attendees.

Sensus Healthcare (NASDAQ: SRTS) has announced the publication of a significant study in the Annals of Plastic Surgery demonstrating the effectiveness of their SRT-100® system in preventing keloid recurrence. The study, conducted at Tri Service Military Hospital in Taiwan, evaluated the combination of surgical keloid excision with primary wound closure followed by Superficial Radiation Therapy (SRT).

The research, involving 12 patients with 16 keloids, showed no keloid recurrence in most patients during follow-up periods exceeding six months. This marks Sensus Healthcare's first study in Asia, with the hospital utilizing the SRT-100® since 2023.

The study's results are particularly significant as keloids, which are benign skin tumors caused by abnormal scar tissue growth, traditionally show high recurrence rates with conventional treatments like corticosteroid injections, cryotherapy, and laser therapy. The integration of SRT targets excess fibroblast activity, addressing the root cause of keloid regrowth.